Head to Head Comparison: TapImmune (NASDAQ:MRKR) versus SAGE Therapeutics (NASDAQ:SAGE)

TapImmune (NASDAQ:MRKR) and SAGE Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Risk and Volatility

TapImmune has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, SAGE Therapeutics has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Institutional & Insider Ownership

33.6% of TapImmune shares are held by institutional investors. 23.7% of TapImmune shares are held by company insiders. Comparatively, 4.6% of SAGE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares TapImmune and SAGE Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TapImmune $210,000.00 1,884.34 -$147.96 million ($1.67) -5.21
SAGE Therapeutics $90.27 million 105.29 -$372.88 million ($8.08) -23.00

TapImmune has higher earnings, but lower revenue than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than TapImmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for TapImmune and SAGE Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TapImmune 0 0 5 1 3.17
SAGE Therapeutics 1 1 13 0 2.80

TapImmune presently has a consensus price target of $10.90, indicating a potential upside of 25.31%. SAGE Therapeutics has a consensus price target of $202.15, indicating a potential upside of 8.79%. Given TapImmune’s stronger consensus rating and higher possible upside, analysts plainly believe TapImmune is more favorable than SAGE Therapeutics.

Profitability

This table compares TapImmune and SAGE Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TapImmune N/A -113.66% -102.04%
SAGE Therapeutics N/A -43.47% -40.57%

Summary

TapImmune beats SAGE Therapeutics on 9 of the 14 factors compared between the two stocks.

TapImmune Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.